Ascendis Pharma AS will present new data on its treatments at the upcoming ASBMR conference.
Ascendis Pharma AS is set to share its latest advancements in hypoparathyroidism and achondroplasia programs at the ASBMR 2026 conference. The company's stock closed at US$225.78, down 0.87% for the day, with a decline of 16.45% over the past month and a year-to-date decrease of 2.21%.
Advertisement
Ascendis Pharma AS
ASND.US
ASND.US
Ascendis Pharma AS
WealthAwesomeMarket cap
$15.42B
P/E
17.6x
52W high
$282.15
52W low
$188.07
1W change
+5.24%
Beta
0.48
Analyst Price Targets
Based on 21 analysts covering ASND · as of Oct 22, 2026
Wall Street analysts forecast ASND stock price to rise 28.8% over the next 12 months.
Consensus
Strong Buy4.76 / 5.00
Avg. Target
C$307.62
+28.8% Upside
Previously C$306.65 on Oct 21, 2026
Current Price
C$238.90
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ASND's historical volatility
30-Day Vol
43.5%
Annualized
90-Day Vol
38.8%
Annualized
Trend (90d)
-26.5%
Annualized drift
90d Mean
C$217.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$231.49 | C$199.23 – C$268.97 |
| 60 trading days | C$224.31 | C$181.42 – C$277.34 |
| 90 trading days | C$217.35 | C$167.61 – C$281.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on the outcomes of the ASBMR presentation for potential impacts on the company's future performance.
Ascendis' stock volume reaches 43,246 shares, slightly above average.
The latest trading volume is 1.13 times the 20-day average of 910,835 shares, indicating a modest increase in trading activity.
Bull case
The presentation could boost investor confidence in Ascendis' innovative therapies, which might lead to greater interest in the stock.
Bear case
If the data presented falls short of expectations, it could negatively impact investor sentiment and the stock's performance.
Event Overview
Advertisement
Ascendis Pharma AS announced that it will present its latest advances in treatments for hypoparathyroidism and achondroplasia at the upcoming ASBMR 2026 conference. This presentation is expected to highlight the company's innovative therapeutic approaches, which could enhance its market position. The timing comes as Ascendis faces a challenging stock performance, with a 1-month decline of 16.45% and a year-to-date drop of 2.21%.
Stock Performance Details
As of the latest trading session, Ascendis' stock closed at US$225.78, reflecting a decrease of 0.87% for the day. The stock has also seen a decline of 0.89% over the past week. Currently, it is trading 9.2% below its 50-day moving average of US$248.70 and 4.2% below its 200-day moving average of US$235.57. The stock's 52-week range is between US$186.05 and US$282.15, indicating that it is currently at 41% of its range.
Looking Ahead
The upcoming presentation at ASBMR 2026 will be closely watched by investors and analysts alike. The average analyst target for Ascendis is US$307.57, suggesting a potential upside of 36.2% from the current price. With a P/E ratio of 17.47 and a profit margin of 70.9%, the company has shown strong fundamentals, which could be enhanced by positive data from the conference. Investors are eager to see how this will influence not only Ascendis' stock performance but also the broader perception of its therapeutic approaches in the healthcare sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
